Characteristics of drugs presented at PDAC hearings
| Drug name | Drug company | # of speakers | # of speakers with COIs |
| Serdolect (sertindole) | Lundbeck | 2 | 0 |
| Seroquel XR (quetiapine fumarate) | Astra Zeneca Pharmaceuticals | 14 | 1 |
| Geodon, Seroquel, Zyprexa | Pfizer Inc., Astra Zeneca Pharmaceuticals, Eli Lilly and Company | 23 | 1 |
| Adasuve (loxapine) | Alexza Pharmaceuticals | 2 | 2 |
| Probuphine (buprenorphine hydrochloride and ethylene vinyl acetate) | Titan Pharmaceuticals Inc. | 11 | 6 |
| Chantix (varenicline tartrate) | Pfizer Inc | 7 | 0 |
| Gepirone hydrochloride XR | Fabre-Kramer Pharmaceuticals Inc. | 7 | 2 |
| Probuphine (buprenorphine hydrochloride and ethylene vinyl acetate) | Titan Pharmaceuticals Inc. | 18 | 8 |
| Vortioxetine | Takeda Development Center Americas, Inc. | 6 | 5 |
| Nuplazid (pimavanserin) | Acadia Pharmaceuticals Inc. | 15 | 8 |
| Lofexidine hydrochloride | US WorldMeds, Inc. | 6 | 2 |
| Buprenorphine and samidorphan | Alkermes | 13 | 5 |
| Brexanolone | Sage Therapeutics | 14 | 9 |
| Esketamine 28 mg single-use nasal spray device | Janssen Pharmaceuticals, Inc. | 7 | 3 |
COI, conflicts of interest; PDAC, Psychopharmacologic Drug Advisory Committee.